Leiderman Elisabeth 4

What Happened Elisabeth Leiderman, a director of Autolus Therapeutics plc (AUTL), received two restricted stock unit (RSU) awards on June 29, 2026 totaling 79,167 RSUs (31,667 and 47,500). The Form 4 reports these as derivative awards with an acquisition price of $0 per RSU (standard for compensation awards) — the filing shows $0 since these are grants, not open-market purchases or sales.

Key Details

• Transaction date: June 29, 2026; Form 4 filed July 1, 2026 (timely within the usual 2-business-day window).
• Award details: 31,667 RSUs and 47,500 RSUs; total = 79,167 RSUs; reported acquisition price $0 (derivative).
• Shares owned after transaction: not specified in the submitted Form 4.
• Relevant footnotes from the filing:
  • F1: Each RSU is a contingent right to one American Depositary Share (ADS); each ADS is convertible 1:1 into one ordinary share at the reporting person’s option.
  • F2: The RSUs vest in one installment on June 29, 2027 (one-year cliff).
  • F3: Separate share options referenced vest in 12 equal monthly installments beginning July 29, 2026.

Context RSU grants are typically compensation awards and do not represent immediate share ownership or sales; the RSUs convert to ADSs (and then to ordinary shares if the holder elects) only upon vesting and any required settlement. Because this filing reports the award (code "A") rather than a market purchase or sale, it’s best interpreted as a grant tied to service or board duties rather than a direct market signal.